SAN FRANCISCO & LEUVEN, Belgium–(BUSINESS WIRE)–Unlearn®, a frontrunner in AI options for scientific trials, right now introduced outcomes from a collaboration with remynd, a Belgium-based biotech firm creating therapies for neurodegenerative illnesses. The outcomes had been shared on the 2025 Alzheimer’s & Parkinson’s Drug Growth Summit in Boston.
The collaboration targeted on remynd’s Section 2a scientific trial of REM127, an investigational, first-generation small molecule remedy concentrating on septins in sufferers with mild-to-moderate Alzheimer’s Illness (AD). The research enrolled a restricted variety of contributors and measured modifications in AD biomarkers over a brief remedy window.
Unlearn supported the research by making use of its Alzheimer’s Illness-specific Digital Twin Generator (AD DTG)—a proprietary machine studying mannequin skilled on knowledge from greater than 26,000 contributors throughout landmark AD datasets reminiscent of ADNI, CPAD, NACC, and EPAD. The AD DTG makes use of every participant’s baseline knowledge to forecast their scientific and biomarker trajectories beneath normal care, producing a “digital twin” for each particular person within the trial.
These digital twins served as individualized comparators, offering an extra layer of proof to assist interpret modifications noticed within the handled inhabitants. This method is especially invaluable in early-phase research the place small pattern sizes restrict the flexibility to attract conclusions utilizing conventional statistical strategies alone.
“This can be a highly effective instance of how digital twins might help unlock insights from small research,” stated Steve Herne, CEO of Unlearn. “Our collaboration with remynd helped strengthen the proof behind REM127 and demonstrated the worth of utilizing AI to help smarter, quicker scientific analysis.”
“The collaboration with Unlearn and the ensuing knowledge additional will increase our confidence in our pioneering method in the direction of reaching symptomatic reduction and illness modification in Alzheimer’s. This can help our efforts to advance an optimized second-generation remedy,” stated Gerard Griffioen, Ph.D., CSO of remynd. “Digital twins provide a brand new lens for decoding biomarker tendencies over time—particularly in early-stage trials the place each knowledge level issues.”
For extra info, go to www.unlearn.ai or comply with us on LinkedIn and X/Twitter.
